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Abstract
Background: An increasing number of studies show that genetic markers can aid in refining prognostic
information and predicting the benefit from systemic therapy. Our goal was to develop a high throughput, cost-
effective and simple methodology for the detection of clinically relevant hot spot mutations in colon cancer.
Methods: The Maldi-Tof mass spectrometry platform and OncoCarta panel from Sequenom were used to profile
239 colon cancers and 39 metastatic lymph nodes from NSABP clinical trial C-07 utilizing routinely processed FFPET
(formalin-fixed paraffin-embedded tissue).
Results: Among the 238 common hot-spot cancer mutations in 19 genes interrogated by the OncoCarta panel,
mutations were detected in 7 different genes at 26 different nucleotide positions in our colon cancer samples.
Twenty-four assays that detected mutations in more than 1% of the samples were reconfigured into a new
multiplexed panel, termed here as ColoCarta. Mutation profiling was repeated on 32 mutant samples using
ColoCarta and the results were identical to results with OncoCarta, demonstrating that this methodology was
reproducible. Further evidence demonstrating the validity of the data was the fact that the mutation frequencies of
the most common colon cancer mutations were similar to the COSMIC (Catalog of Somatic Mutations in Cancer)
database. The frequencies were 43.5% for KRAS, 20.1% for PIK3CA, and 12.1% for BRAF. In addition, infrequent
mutations in NRAS, AKT1, ABL1, and MET were detected. Mutation profiling of metastatic lymph nodes and their
corresponding primary tumors showed that they were 89.7% concordant. All mutations found in the lymph nodes
were also found in the corresponding primary tumors, but in 4 cases a mutation was present in the primary tumor
only.
Conclusions: This study describes a high throughput technology that can be used to interrogate DNAs isolated
from routinely processed FFPET and identifies the specific mutations that are common to colon cancer. The
development of this technology and the ColoCarta panel may provide a mechanism for rapid screening of
mutations in clinically relevant genes like KRAS, PIK3CA, and BRAF.
Trial Registration: ClinicalTrials.gov: NSABP C-07: NCT00004931
Background
Recent evidence suggests that mutation profiling can
assist in the prognosis and prediction for colon cancer.
KRAS, PIK3CA and BRAF mutations are frequent in
tumors of the colon and have been associated with poor
prognosis [1-6]. However, these results remain contro-
versial because other studies have shown that mutations
in these genes are not prognostic. A large study, a meta
analysis, of KRAS mutations, found that only
KRASG12V was a bad prognostic marker; other KRAS
mutations were not associated with bad prognosis [2].
Evidence has also demonstrated that KRAS mutations
are potential markers for prediction because tumors
with KRAS mutations are significantly associated with
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Publications have reported the same phenomenon with
BRAF and PIK3CA mutations, although these observa-
tions are still not well established [12,13]. The published
study suggesting that BRAF mutant tumors were resis-
tant to EGFR therapies was a small study [13]. Predic-
tive value of PIK3CA mutations remains controversial in
that other publications have shown that these mutations
have no predictive value [14,15]. These inconsistencies,
together with two other factors, have limited the impact
of mutation profiling for prognosis and prediction in
standard care of colon cancer. A large sample size is
required to establish that a gene mutation has a signifi-
cant impact for patient prediction or prognosis. Another
limitation is that until recently conducting such large
studies with the standard sequencing technologies was
too time consuming and too expensive to be practical
for clinical studies.
Moreover, while the high frequency of KRAS, BRAF
and PIK3CA mutations in colon cancer is well docu-
mented, other potentially important mutations have not
been profiled with a large number of clinical samples.
Whole genome sequencing of a small number of colon
samples demonstrated that somatic cancer mutations
consist of a few genes that occur frequently and many
more mutations that occur very infrequently in many
different genes [16,17]. Mutations in these infrequently
mutated genes could have a similar effect or synergize
with mutations in KRAS, PIK3CA, and BRAF.
Given these considerations, our goal was to find a
cost-effective and high throughput methodology that
would detect frequent and infrequent cancer mutations
genes in a large number of samples. Furthermore, it was
essential that the methodology would work with
degraded DNAs isolated from FFPET.
The mass spectrometric SNP genotyping technology
based on the Sequenom platform provided an ideal
choice for mutation profiling to address these several
criteria. It has been shown to work with small amounts
of degraded DNAs (5 ng), and the high multiplexing
capacity minimizes the use of irreplaceable clinical sam-
ples. In addition, a variety of studies have demonstrated
that the sensitivity of mass spectrometric methods
exceeds that of traditional Sanger sequencing and is
highly concordant with Sanger sequencing, Pyrosequen-
cing, and allele-specific PCR [16,18,19]. Furthermore,
Sequenom has recently developed the OncoCarta Panel,
an oncogene panel that offers a rapid and parallel analy-
sis of 238 simple and complex cancer mutations across
19 genes.
The OncoCarta panel includes assays for most colon
cancer mutations in the clinically relevant genes, BRAF
(99%), KRAS (98%), and PIK3CA (78%), and in addition
contains assays for other cancer mutations in genes that
intersect with the same pathways as that of KRAS,
BRAF, and PIK3CA, such as AKT1, EGFR, HRAS, NRAS,
MET and others. The frequency of KRAS, PIK3CA,a n d
BRAF mutations in the National Surgical Adjuvant
Breast and Bowel Project (NSABP) trial C-07 were simi-
lar to the frequencies for colon samples listed in the
COSMIC data base. This observation provides evidence
that the mutation data obtained with the Sequenom
platform is accurate. Our results also demonstrate that a
majority of colon cancer samples have aberrant PIK(3) -
RAS/RAF network; similar results have been seen pre-
viously [6].
Mutations in ABL1 and MET, not previously identified
in colon cancer, were identified, and 13 other genes
were screened and found not to be mutated in hot spot
locations. Furthermore, this study identified the most
frequent colon cancer mutations from OncoCarta, pro-
viding the necessary information to reduce the number
of assays from 187 to 24, creating a smaller, more speci-
fic and economical panel, requiring less DNA, and thus
conserving precious clinical samples.
Methods
Clinical samples and histological evaluation
Samples used in this study were from NSABP clinical
trial C-07. This trial enrolled patients between 02/2000
and 11/2002 to compare oxaliplatin and bolus 5-FU/LV
to bolus 5FU/LV alone for resected stage II and III
colon cancer [20]. Tissue samples were obtained at sur-
gery before the patients had received any treatment and
were routinely processed with FFPE. C-07 was approved
by an institutional review board, and informed consent
was obtained from each subject. A pathologist categor-
ized tumors into poor, moderate, well differentiated and
signet cells carcinoma, according to the World Health
Organization (WHO) criteria. Samples were graded for
mucinous character, based on the amount of mucin
retained within the tumor (1 = no mucin, 2 = < 50%
mucinous volume/total tumor volume, 3 = >50% muci-
nous volume/total tumor volume). Only grade 3 tumors
were considered mucinous tumors carcinoma, which is
in accordance with WHO criteria.
DNA isolation
DNA was isolated from FFPE tumor blocks collected
from patients participating in NSABP clinical trial C-07.
FFPE tumor blocks were cut, and sections of the slide
containing the most tumor cells were defined by a
pathologist and isolated by macrodissection. Genomic
DNA was extracted from 4 five μm unstained sections.
After attempting several extraction procedures from a
variety of manufacturers (Machery Negel, Qiagen,
Ambion), it was determined that the Ambion Recover-
All™ Total Nucleic Acid isolation kit (Applied Biosystem,
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quality, quantity, and the performance on the mass
spectrometer (data not shown). The extraction was per-
formed as recommended by the manufacturer, with two
exceptions; the protease digestion was extended over-
night and the elution volume was increased to 150 ul to
maximize the total amount of DNA recovered. Addi-
tional protease was added to samples incompletely
digested after the overnight treatment. DNA was mea-
sured with fluorescence, using the Quant-iT ™ Pico-
Green® dsDNA Assay Kit (Invitrogen, Carlsbad, CA) and
the InfiniteF200 fluorometer (Tecan, Mannedorf,
Switzerland).
As a positive control for known mutations and to test
the performance of the platform, annotated cell line
DNAs (A2058, HS578T, HL60, MCF7, MDAMB231,
NCI-H1299, NCI-H1395, UACC-893) were purchased
from American Type Culture Collection (ATCC, Mana-
ssas, VA, US). Two cell lines, SKBR3 and MCF-7, were
grown in culture and cell pellets were fixed in formalin,
andembedded in paraffin and DNAs were isolated as
described for the clinical samples.
Mass Spec Type Plex Technology and the
OncoCarta Panel
For mutation detection, the Sequenom platform and
the OncoCarta mutation panel were used and the pro-
tocol provided by Sequenom (San Diego, CA) was fol-
lowed with minor modifications. A schematic of the
procedure is shown in Fig. 1. A Tecan Evo liquid
handler was used to normalize the DNA samples and
to set up the PCR reactions. The amount of DNA
Figure 1 Methodology for mutation detection. Genomic DNA from the samples is amplified by PCR, resulting in copies of both mutant and
wildtype alleles. Shrimp Alkaline Phosphatase removed excess nucleotides from the sample wells. Primer extension was performed using
terminator nucleotides A, C, T, G, each with distinct masses. This linear amplification results in sequences proportional to the alleles that can be
distinguished by mass spec (Maldi-Tof Separation).
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were amplified using the OncoCarta PCR primer pools,
unincorporated nucleotides were inactivated by shrimp
alkaline phosphatase (SAP), and a single base extension
reaction was performed using extension primers that
hybridize immediately adjacent to the mutations and a
custom mixture of nucleotides. Salts were removed by
t h ea d d i t i o no fac a t i o ne x c h a n g er e s i n .M u l t i p l e x e d
reactions were spotted onto the SpectroChipII, and
mutations, if present, were resolved by MALDI-TOF
on the Compact Mass Spectrometer (Sequenom, San
Diego, CA).
The OncoCarta™ Panel v1.0 (Sequenom, San Diego,
CA) consists of 24 pools of primer pairs and 24 pools of
extension primers, and has the capacity to detect 238
mutations in 19 genes, listed in Table 1. Each pool con-
sists of 5-9 primer pairs in the PCR reaction. Two types
of assays have been designed in the OncoCarta panel,
referred to as simple and complex. The simple assays
a r et h o s ei nw h i c has i n g l ea s s a yi sa b l et od e t e c tt h e
amino acid changes at that codon. The complex assays
a r et h o s et h a tr e q u i r em o r et h a no n ea s s a yt oi d e n t i f y
codon changes or deletions and insertion, and thus are
able to detect multiple different amino acid substitutions
or deletions. An example of a complex assay is KRAS_1
and KRAS_2, which interrogate 2 different nucleotide
positions within codon 12 and together identify all
codon 12 amino acid changes. Much more complex
assays are included in OncoCarta, which interrogate
insertions and deletions within the EGFR gene.
Data analysis
Data analysis was performed using MassArray Typer Ana-
lyzer software 4.0.4.20 (Sequenom), which facilitates visua-
lization of data patterns as well as the raw spectra.
Mutations were identified in two different ways. Typer
automates the identification of mutants by comparing
ratios of the wild type peak to that of all suspected
mutants and generates an Onco Mutation report detailing
specific mutations and the ratios of wild type and muta-
tion peaks. In addition, raw data was exported to Excel
and an in-house macro was used to duplicate the analysis.
T h ea r e au n d e rt h ep e a k sa l l o w sf o rq u a n t i f i c a t i o nf o r
each allele, giving a direct evaluation of the proportion of
mutated and wildtype (wt) allele in the sample [18].
All mutations from both the Onco mutation report
and the in-house Excel report were reviewed manually
by 3 investigators (DF, PGG, KPG). Manual review of
mutations was necessary to identify “real” mutant peaks
from salt peaks or other background peaks. Selected
reviewed mutations from the Onco Mutation Report
and from the in-house macro were compared and were
concordant.
Results
Mutations were detected in control DNAs from intact and
FFPETsamples
Previously described mutations in control cell lines were
detected. BRAF_V600E, HRAS_G12D, NRAS_Q61L,
PIK3CA_E545K, KRAS_G13D, NRAS_Q61K,
EGFR1_S125L, and PIK3CA_H1047R were detected in
the appropriate cell lines (A2058, HS578T, HL60,
MCF7, MDAMB231, NCI-H1299, NCI-H1395, and
UACC-893, respectively). The appropriate mutation was
found in MCF-7 (PIK3CA_E545K) from both intact
DNA and DNA isolated from FFPET. DNAs from clini-
cal samples, control cell lines, and cell lines formalin-
fixed, paraffin-embedded cell lines showed the same
rates of primer extension and performance on mass
spectrometer.
The proportion of the mutated alleles in each cell line,
as observed from the area under the mutant peak on
the spectra, ranged from 0.4-0.6, as expected for a pure
clonal population with a heterozygote mutation. Spectra
for cell line UACC-893 had equal fractions of mutant
and wt alleles (Fig. 2A). One exception to this distribu-
tion among cell lines was seen in A2058, which showed
spectra consistent with 2 copies of the WT allele and
one mutant BRAF mutant allele (Fig. 2B). The 3 alleles
of BRAF in A2058 are consistent with the observation
that there are 3 copies of chromosome 7 in this cell line
(COSMIC in the SNP Array Based LOH and Copy
Number Analysis data base) [21].
The Sequenom platform was sensitive and quantitative
Pilot studies demonstrated that the assays worked with
as little as 1 ng of DNA (Fig. 3). The fraction of unex-
tended primer was .09 even when the input DNA was
between 1-3 ng, When concentrations of the amount of
DNA was between 3-14 ng, the fraction of unextended
primer was similar, .07. Thus, the assays worked well
even when only 1 ng of DNA was used.
In clinical samples with some assays it was possible to
detect mutations that only represented 5% of the total 2
peak areas. The spectra in Fig. 4 show a small but clear
peak at the expected size for a PIK3CA 1047R mutation
in a lymph node. We also were able to demonstrate the
sensitivity of the platform by performing a cell mixing
experiment. Mutation analysis was done using MCF-7
cell line DNA alone or mixed with SKBR3 at various
percentages. MCF-7 cells contain a PIK3CA mutation,
and SKBR3 cells do not. Fig. 5 demonstrates that the
mutation was detectable even when the MCF-7 cells
represented only 5 to 10% of the total DNA and only 5
to 2.5% of the alleles. This sensitivity is important for
mutation detection in clinical cancer samples, which
usually contain some amount of normal tissue, which
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Page 4 of 14Table 1 Mutations detected with OncoCarta
ABL1-G250E EGFR-L747_E749del, A750P KIT-P585P
ABL1-Q252H EGFR-E746_A750del KIT-D579del
ABL1-Y253H EGFR-L747_E749del, A750P KIT-K642E
ABL1-Y253F EGFR-L747_S752del, P753S KIT-D816V
ABL1-E255K EGFR-E746_T751del, V ins KIT-D816H/D816Y
ABL1-E255V EGFR-L747_S752del, Q ins KIT-V825A
ABL1-D276G EGFR-L747_S752del, Q ins KIT-E839K
ABL1-F311L EGFR-E746_T751del, S752D/SNP C2255T KIT-M552L
ABL1-T315I EGFR-D770_N771>AGG/V769_D770insASV/V769_D770insASV KIT-Y568D
ABL1-F317L EGFR-D770_N771insG KIT-F584S
ABL1-M351T EGFR-L747_T750del, P ins KIT-P551_V555del
ABL1-E355G EGFR-E746_A750del KIT-P551_V555del
ABL1-F359V EGFR-E746_T751del, I ins KIT-Y553_Q556del
ABL1-H396R EGFR-L747_T751del KIT-Y553_Q556del
AKT1-rs11555435 EGFR-L747_T751del KRAS-G12V/A/D/C/S/R/F
AKT1-rs11555431 EGFR-E746_A750del, V ins KRAS-G13C/S/V/D
AKT1-rs11555432 EGFR-E746_A750del, V ins KRAS-A59T
AKT1-rs12881616 EGFR-S752_I759del KRAS-Q61E/K/L/R/P/H
AKT1-rs11555433 ERBB2-L755P MET-R970C
AKT1-rs11555436 ERBB2-G776S/G776LC MET-T992I
AKT1-rs34409589 ERBB2-G776VC MET-Y1230C
AKT2-S302G ERBB2-G776VC/G776VC MET-Y1235D
AKT2-R371H ERBB2-M774_A775insYVMA MET-M1250T
BRAF-G464R ERBB2-A775_G776insYVMA NRAS-G12V/G12A/G12D
BRAF-G464V/G464E ERBB2-P780_Y781insGSP NRAS-G12C/G12R/G12S
BRAF-G466V/G466G/G466E ERBB2-P780_Y781insGSP NRAS-G13V/G13A/G13D
BRAF-G466R ERBB2-S779_P780insVGS NRAS-G13C/G13R/G13S
BRAF-F468C FGFR1-S125L NRAS-A18T
BRAF-G469S/E/A/V/R FGFR1-P252T NRAS-Q61L/Q61R/Q61P
BRAF-D594V| G FGFR3-R248C NRAS-Q61H
BRAF-F595L FGFR3-S249C NRAS-Q61E/Q61K
BRAF-G596R FGFR3-G370C PDGFRA-V561D
BRAF-L597S/R/Q/V FGFR3-Y373C PDGFRA-T674I
BRAF-T599I FGFR3-A391E PDGFRA-F808L
BRAF-V600E/K/R/L FGFR3-K650Q/E PDGFRA-D846Y
BRAF-K601N/E FGFR3-K650T/M PDGFRA-N870S
CDK-R24C/H FLT3-I836del PDGFRA-D1071N
EGFR-R108K FLT3_2 PDGFRA-D842_H845del
EGFR-T263P FLT3_3 PDGFRA-I843_D846del
EGFR-A289V FLT3-D835H/D835Y PDGFRA-S566_E571>K
EGFR-G598V HRAS-G12V/D PDGFRA-I843_S847>T
EGFR-E709K/E709H HRAS-G13C/R/S PDGFRA-D842V
EGFR-E709A/E709G/E709V HRAS-G13V/D PIK3CA-R88Q
EGFR-G719S/G719C HRAS-Q61H PIK3CA-N345K
EGFR-G719A HRAS-Q61H/L/R/P/K PIK3CA-C420R
EGFR-M766_A767insAI JAK2-V617F PIK3CA-P539R
EGFR-S768I KIT-D52N PIK3CA-E542K
EGFR-V769_D770insASV KIT-Y503_F504insAY PIK3CA-E545K
EGFR-V769_D770insCV KIT-W557R/W557R/W557G PIK3CA-Q546K
EGFR-D770_N771>AGG/V769_D770insASV/V769_D770insASV KIT-V559D/V559A/V559G PIK3CA-H701P
EGFR-D770_N771insG KIT-V559I PIK3CA-H1047R/H1047L
EGFR-N771_P772>SVDNR KIT-V560D/V560G PIK3CA-H1047Y
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concern when profiling lymph nodes, which may con-
tain a minority of tumor cells.
Frequencies of C-07 mutations in KRAS, NRAS, PIK3CA,
and BRAF detected with OncoCarta and the Sequenom
platform were similar to previous reports
In this preliminary assessment of the feasibility of using
the Sequenom platform to do large-scale mutation profil-
ing of colon cancer samples isolated from FFPET, it was
essential to determine if our data yielded frequencies
typical of what has been seen previously. Table 2 shows
the mutation frequencies obtained here and from the
COSMIC (Catalog of Somatic Mutations in Cancer)
database [21]. The COSMIC frequencies seen in Table 2
are based only on those mutations that are detectable
with OncoCarta. OncoCarta assays interrogate 99%, 98%,
and 78% of the known colon cancer mutations in BRAF,
KRAS,a n dPIK3CA, respectively, based on a large num-
ber of colon cancer samples that have been sequenced in
BRAF (n = 4628), KRAS (n = 858) and PIK3CA (n = 247).
The OncoCarta panel found that the most frequent
mutations in C-07 were KRAS (43.5%), PIK3CA (20.1%),
and BRAF (12.1%), which are similar to what is seen in
COSMIC. NRAS mutations, while infrequent, were
detected in codons 12, 13 and 61 and represent a sizable
minority of the C0-7 samples (3.8%). These data suggest
Table 1: Mutations detected with OncoCarta (Continued)
EGFR-P772_H773insV KIT-K550_K558del PIK3CA-G1049R
EGFR-H773>NPY KIT-K558_V560del PIK3CA-R38H
EGFR-H773_V774insNPH/H773_V774insPH/H773_V774insH KIT-K558_E562del PIK3CA-C901F
EGFR-V774_C775insHV KIT-V559del PIK3CA-M1043I/M1043I
EGFR-T790 M KIT-V559_V560del RET-C634R
EGFR-L858R KIT-V560del RET-C634W/Y
EGFR-L861Q KIT-Y570_L576del RET-E632_L633del
EGFR-L747_T750del, P ins/E746_A750del, T751A KIT-E561K RET-M918T
EGFR-E746_T751del, I ins/S752_I759del KIT-L576P RET-A664D
Figure 2 Spectra for cell lines UACC-893 and A2058. The expected positions for the unexteneded primer (UEP), and the extension products
(Mutant and WT) from assays PIK3CA_9 and BRAF_15 in cell lines UACC-893 and A2058, respectively, are indicated with red dashed lines. The
proportion of peak areas and the specific base is also shown. Assays PIK3CA_9 and BRAF_15 detected mutations in PIK3CA at amino acid position
1047 and in BRAF at amino acid position 600, respectively. Other peaks included in these spectra as result of multiplexing but not part of the
designated assays are indicated as grey dashed lines.
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amounts of input DNA into the PCR reactions are shown. The number of samples used in each category was 4 for 1-3 ng, 9 for 3-9 ng, 13 for
9-13 and 210 for 14 ng.
Figure 4 Sensitive detection of mutations in clinical FFPE samples with the Sequenom platform. Small mutant but definitive peak
illustrating a PIK3CA-1047R mutation in approximately 5% of the sample DNA is shown.
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nology described here and yield accurate data.
While most of the specific amino acid mutations mir-
ror what is seen on the COSMIC database, some unique
colon cancer gene mutations were found, which include
ABL1-F359V, AKT1-E17K, MET-R970C, and MET-
T992I. Other amino acid changes that were not in the
COSMIC database were amino acid changes R88Q,
H701P, and C420R in PIK3CA, BRAF-594V/G, and
KRAS-Q61R, and several in NRAS, including G12C,
G12D, G13R, G13V, Q61H and Q61K (Table 2).
MET mutations were found in C0-7 and amplified in
sometumors
MET mutations were found in 3.3% of C-07 samples.
Interestingly, these mutations were not only unexpected
in their appearance within the colon cancer population
but also the frequency within the samples was unex-
pected. In four of the eight samples with MET muta-
tions, the mutant alleles were present at 58-70%,
suggesting an amplification of the mutant allele or a loss
of the wt gene (Fig. 6). Amplification may represent the
best explanation, in that amplification of the MET geno-
mic region, 7q31, has been observed in the Progenetix
CGH Database in 23% of colorectal cancers [22]
Sequenom data was reproducible
Most of the assays in the OncoCarta panel did not
detect mutations or the frequency of mutations was
very low (below 1%) in our colon cancer samples.
OncoCarta assays interrogate mutations in these 19
genes listed in Table 1. To reduce the cost, time and
the amount of DNA required for profiling, only 24
assays, which detected mutations at a frequency of 1%
or greater in C-07, were selected, resorted in 6 pools
and included in a new panel, termed ColoCarta (Table
3). Mutation profiles of 32 mutant samples with 41
mutations were repeated with the ColoCarta. The
mutations detected by the 2 panels (OncoCarta and
ColoCarta) were identical, demonstrating the reprodu-
cibility of the methodology.
Multiple mutation frequencies suggest an order to the
acquisition of different mutations
A majority of the tumors (64%) contained at least one
or more mutations in the following genes: BRAF,
KRAS, NRAS, MET,o rPIK3CA, and 18% had 2 or
more mutations. The most common double mutation
was in KRAS and PIK3CA,f o l l o w e db yPIK3CA and
BRAF (Table 4). Most samples with PIK3CA mutations
(80%) also had mutations in other genes, the most
Figure 5 Quantification of the sensitivity with a cell line mixing experiment. Spectra of MCF-7 cells (mutant) alone or mixed with SKBR3
cells (WT) are shown. Percents are based on the ng amounts of DNA. This assay detects an E545K mutation in PIK3CA.
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were BRAF, MET, NRAS,a n das e c o n dPIK3CA muta-
tion (Table 2, last column). Tumors with MET and
NRAS mutations also have an unexpectedly high fre-
quency of co-occurring mutations, which suggests that
they occur as a second mutation and perhaps later in
the etiology of the tumor. Many tumors contain only a
KRAS or BRAF mutation, which is consistent with pre-
vious reports finding these mutations in earlier stages
of colon cancer [23,24]. The multiple mutation fre-
quencies for tumors with KRAS and PIK3CA or with
PIK3CA and BRAF were slightly higher and lower,
respectively, than expected based on their individual
frequencies (Table 4). Conversely, the expected double
mutation frequency of BRAF and KRAS would be 5.1%,
based on our data, but this combination was not
found, also in agreement with previous reports [24]
(Table 4).
Table 2 Frequency of colon cancer mutations
Mutation No. Mutated Samples Frequency in Primary Tumor* in COSMIC
† Multiple Mutations
‡
ABL1-F359V 1 0.40% 0/66
§
ABL1 Total 1 0.40% NF(0/66)
§ 100%
AKT1-E17K 1 0.40% 0/31
§
AKT1 Total 1 0.40% NF(0/31)
§ 100%
BRAF-D594V| G 1 0.40% NF (0/3179)
BRAF-V600E 28 11.70% 14.60%
BRAF Total 29 12.10% 14.70% 24%
KRAS-G12A 2 0.80% 1.80%
KRAS-G12C 10 4.20% 3.60%
KRAS-G12D 40 16.70% 13.20%
KRAS-G12R 3 1.30% 0.40%
KRAS-G12S 3 1.30% 4.20%
KRAS-G12V 20 8.40% 7.40%
KRAS-G13D 23 9.60% 5.20%
KRAS-A59T 1 0.40% 0.10%
KRAS-Q61L 1 0.40% 0.20%
KRAS-Q61R 1 0.40% NF (0/1927)
KRAS Total 104 43.50% 36.10% 34%
MET-R970C 2 0.80% NF (0/77)
MET-T992I 6 2.50% NF (0/77)
MET Total 8 3.30% 0% 50%
NRAS-G12C 1 0.40% NF (0/46)
NRAS-G12D 4 1.70% NF (0/46)
NRAS-G13R 1 0.40% NF (0/46)
NRAS-G13V 1 0.40% NF (0/46)
NRAS-Q61H 1 0.40% NF (0/46)
NRAS-Q61K 1 0.40% NF (0/46)
NRAS Total 9 3.80% 2.2% 38%
PIK3CA-R88Q 5 2.10% NF (0/171)
PIK3CA-C420R 2 0.80% NF (0/171)
PIK3CA-E542K 9 3.80% 4.10%
PIK3CA-E545K 12 5.00% 4.10%
PIK3CA-Q546K 4 1.70% 1.20%
PIK3CA-H701P 1 0.40% NF (0/171)
PIK3CA-H1047L 1 0.40% 1.80%
PIK3CA-H1047R 14 5.90% 5.30%
PIK3CA Total 48 20.10% 16.40% 80%
*% of C-07 samples with this mutation.
†Data from COSMIC for colon adenocarcinoma limited to the same mutations interrogated with OncoCarta. The mutations listed are only the ones found in C-07.
Some COSMIC amino acid changes are not shown here if they were not mutated in C-07.
‡% of samples with a mutation in the gene shown and at least one other mutation in C-07 samples.
§COSMIC data are from large intestine, not specific to colon.
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with respect to the frequency of these mutant alleles
In the samples with co-occurring mutations, the ratios
of KRAS mutation ratio (KRAS mutation peak area/total
peak area) to the PIK3CA mutation ratio (PIK3CA
mutation peak area/total peak area) was determined.
Twenty-two out of 31 samples (71%) had KRAS/PIK3CA
ratios above 1.25 (Table 5). PIK3CA mutations were
more prevalent in only 2 out of 31 samples. These dif-
ferences demonstrate that in a majority of primary
tumors with double mutations in KRAS and PIK3CA,
the KRAS mutations are more prevalent than the
PIK3CA. This unequal distribution of mutant alleles
within a tumor may be due to the fact that a majority of
t h et u m o rc e l l sh a v eo n l yt h eKRAS mutation, and cells
with a PIK3CA mutation are in the minority, or it could
be due to copy number variations in the KRAS and
PIK3CA loci.
BRAF mutations were correlated with poorly
differentiated tumors and with mucinous tumors
The frequency of mutations for KRAS, PIK3CA,a n d
BRAF were tested for correlation to the degree of differ-
entiation and to the prevalence of mucin in the tumor.
BRAF mutations were found in 26.2% of the poorly dif-
ferentiated tumors and in 8.2% of the moderate and well
differentiated. These frequencies were significantly dif-
ferent by Chi square test (p value = 0.001). BRAF muta-
tions were also associated with mucinous tumors: BRAF
mutations occurred in 28% of grade 3 mucinous tumors
(>50% mucinous tumor cells) but in only 9.4% of the
non-mucinous tumors (grade 1 and 2). This was signifi-
cant by the Chi square test at p value = 0.006. Similar
data have been reported previously [25,26]. KRAS and
PIK3CA mutations did not correlate with either the
degree of differentiation or with prevalence of mucinous
cells.
Mutation profiling demonstrated a majority of primary
and lymph node samples were concordant but
differences were detected
Lymph node metastases were not routinely collected in
C-07 but as a pilot study to determine the feasibility of
using lymph nodes for mutation profiling was conducted.
We isolated DNA from 39 lymph nodes containing
tumor cells and their corresponding primary tumors.
These primary and lymph nodes samples were profiled
with the entire OncoCarta panel. The majority of lymph
nodes and their corresponding primary tumors (89.7%)
were concordant. A total of 26 mutations were detected
in lymph nodes, including KRAS, BRAF, PIK3CA,a n d
NRAS. Thirty-five out of 39 lymph nodes had identical
mutation profiles, but in 4 cases mutations in the primary
Figure 6 MET mutation is amplified. The proportion and position
(blue dashed lines) of mutant and wt alleles are shown. The MET_1
assay detects R970C mutations in MET.
Table 3 ColoCarta panel
Sequenom’s Assay Name Amino Acid Change
BRAF_15 &16 V600E/K/R/L
BRAF_9 BRAF-D594V
HRAS_6* HRAS-Q61L
KRAS_1 & 2 G12V/A/D/C/S/R/F
KRAS_4 KRAS-G13D
KRAS_5 KRAS-A59T
KRAS_7 KRAS-Q61L
KRAS_8 Q61H/Q61H
MET_1 MET-R970C
MET_2 MET-T992I
NRAS_1 NRAS-G12V
NRAS_2 NRAS-G12C
NRAS_3 NRAS-G13V
NRAS_4 NRAS-G13C
NRAS_7 NRAS-Q61H
NRAS_8 NRAS-Q61E
PIK3CA_1 PIK3CA-R88Q
PIK3CA_3 PIK3CA-C420R
PIK3CA_5 PIK3CA-E542K
PIK3CA_6 PIK3CA-E545K
PIK3CA_7 PIK3CA-Q546K
PIK3CA_8 PIK3CA-H701P
PIK3CA_9 PIK3CA-H1047R
*HRAS_6 was included in panel but occurred in < 0.1% of samples.
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Page 10 of 14tumors were not found in the corresponding lymph
nodes (BRAF [2], PIK3CA [1] and KRAS [1]).
Mutation profiles demonstrate that tumor cell
populations may be different in lymph nodes and in the
primary tumors
Peak area evaluation of tumors that had 2 mutations
and for which a metastatic lymph node was available
demonstrated differences between the primary and
lymph node samples. Table 6 details the frequency of
mutant and wt alleles based on the peak areas for 5
such samples.
KRAS to PIK3CA ratios demonstrated that there were
more KRAS mutations than PIK3CA mutations in 4 of 4
primary samples, and in 3 of the 4 lymph node samples.
However, it is also notable that the ratio of KRAS/
PIK3A was lower in the lymph node compared to their
primary tumor in 3 out of 4 samples. In sample 0940,
the KRAS/PIK3CA mutation decreased by almost 1/2 in
the lymph node tumor compared to the primary. Thus,
in these samples there is either a loss of KRAS muta-
tions or an accumulation of PIK3CA mutations, suggest-
ing that PIK3CA mutations may impart a selective
advantage in the lymph node.
In contrast, two other samples have a less frequent
occurrence of their PIK3CA mutation in the lymph node
than in the primary tumor. In sample 2244, the PIK3CA
mutation was undetectable in the lymph node (Table 6).
In fact, if there was a selection for both mutations in the
lymph node, then the PIK3CA mutation frequency would
h a v eb e e nt h es a m ea st h a to ft h eKRAS mutation (0.15).
On the other hand, if the PIK3CA/KRAS ratio were the
same in the primary and lymph node tumor, then the
PIK3CA mutation frequency would have been .08, which
is still detectable with this technology (Fig. 3). Thus, in
sample 2244 there were fewer PIK3CA mutant alleles in
the lymph node than in the primary tumor. In sample
1837, mutations in both BRAF and PIK3CA were
detected and the BRAF/PIK3CA ratio was 1.67, but
increased to 4.4 in the metastatic lymph node.
Discussion
The Sequenom platform provides a superior technology
for the screening of many hot spot mutations in cancer
Table 4 Single and double mutations in C-07
Double Mutation Frequencies
KRAS PIK3CA All other
Single Actual Expected Actual Expected Actual Expected
KRAS 43.70% NA NA 10.40% 8.70% 14.60% 7.21%
PIK3CA 20.10% 10.40% 8.70% NA NA 15.50% 8.06%
BRAF 11.80% 0 5.10% 1.80% 2.40% 2.50% 5.71%
MET 3.30% 1.67% 1.44% 0 0.66% 1.67% 2%
NRAS 3.80% 0 1.66% 0.42% 0.40% 1.30% 2.14%
All Mutations 60.20%
Table 5 KRAS/PIK3CA ratio mutation frequencies within
primary tumors
No of Samples KRAS/PIK3CA
22 1.25-3.22
7 0.93-1.13
2 0.81-.42
Average 1.67
Median 1.6
Table 6 Allele frequencies for primary tumors with two mutations and metastatic lymph nodes
Sample Mutations Mutant Allele Frequency Mutation Ratios
Primary Lymph Node Primary M1/M2 Lymph node M1/M2
C07-0388 M1. KRAS-G12D 0.45 0.44 1.88 1.63
M2. PIK3CA-H1047R 0.24 0.27
C07-0717 M1. KRAS-G13D 0.08 0.09 1.14 0.90
M2. PIK3CA-H1047R 0.07 0.1
C07-0940 M1. KRAS-G12D 0.42 0.34 1.91 1.10
M2. PIK3CA-E542K 0.22 0.31
C07-2244 M1. KRAS-G12C 0.37 0.15 1.76 _
M2. PIK3CA-H1047R 0.21 0
C07-1837 M1. BRAF-V600E 0.2 0.22 1.67 4.40
M2. PIK3CA-H1047R 0.12 0.05
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Page 11 of 14samples. Sanger sequencing would require amplification
of at least 60 different fragments per sample, and many
reactions would require optimization, thus adding con-
siderable time and expense. Multiplexing and the use of
the OncoCarta panel allowed us to skip this time con-
suming step. Thus, conservatively, Sanger sequencing
would be 40 times more expensive, and require at least
2 times more DNA. Other sequencing technologies,
which employ differential melting of mutant and wt
sequences, such as HRMA, still require that the PCR
product be sequenced. This would add significant cost
and time to the procedure because 60% of the colon
samples contained one or more mutations. In addition
the Sequenom platform is more sensitive than Sanger
sequencing in that it was able to detect mutations that
represented only 5% of the DNA. Pyrosequencing repre-
sented a potential alternative to the Sequenom platform,
but in our hands assays needed to be optimized, and the
lack of multiplexing made the procedure more time
consuming and demanded more DNA. The Sequenom
methodology also focuses on only those nucleotides that
are known to be cancer mutations and thus makes
review of the sequence information considerably faster
than Sanger. Next-Generation sequencing was cost pro-
hibitive and has not been shown to work with DNAs
isolated from FFPET. Thus, the Sequenom platform and
the OncoCarta Panel provided the simplest, most rapid,
sensitive and cost-effective method for detecting hot
spot cancer mutations in degraded DNAs isolated from
archival and routinely processed FFPET. The ColoCarta
panel provides a more specific panel for colon cancer
mutation detection and greatly reduces the amount of
DNA needed for mutation profiling.
The frequencies and specific amino acid mutations
detected here were similar to the COSMIC database and
other publications [6]. The small variation in frequency
between our data and other reports may be attributed
to differences in the stage of the samples analyzed, the
number of samples considered, and the sensitivity of the
technology [18]. These observations, combined with the
perfect match that we obtained between the expected
and the detected mutations in our control cell lines,
both fresh and FFPE, and the fact that mutations
detected with OncoCarta and ColoCarta were identical,
suggest that the technology is reliable and reproducible
in DNAs isolated from FFPE samples.
In our study, the majority of tumors (60.3%) had one
or more mutations in KRAS, PIK3CA,a n dBRAF. Muta-
tions in these genes are likely to perturb many different
and overlapping signaling pathways, including PI3K/
AKT, ERK/MAPK, SAPK/JNK, NFKb,a n do t h e r s .W e
were also able to detect other less frequent mutations
that are likely to perturb the same pathways and these
may cause resistance to EGFR-targeted therapies, as
reported for KRAS, PIK3CA and BRAF. For example,
AKT1 and NRAS are molecules that are downstream
mediators of the EGFR signaling pathway, and muta-
tions in these genes are likely to affect the response to
drugs that target EGFR.
Mutations in ABL, AKT1, and MET were detected here
but were not listed in COSMIC, probably due to the
small number of samples analyzed. The AKT1-E17K
mutation was initially identified as a SNP, rs34409589,
but in a recent publication it was found to be a somatic
mutation and was found in 3 of 51 colon cancers [27].
The frequency of these mutations in this small study (51
samples) was 6% and is much greater than in the C0-7
samples (0.4%). This difference in frequencies may be
because the Carpten et al [27] samples were from more
advanced stages than those from the C-07 trial. More-
over, they selected large tumors (>100 mg) and contain-
ing more than 60% tumor cells. No such selection was
done for our study, and samples were from stages II and
III exclusively. The significance of ABL1 and AKT1 muta-
tions for patient prediction and prognosis in our study is
questionable given that they each were found in only in
one sample and represented only 0.4% of the cases.
T oo u rk n o w l e d g e ,t h i si st h ef i r s tr e p o r to fMET
mutations in the primary colon cancer, but a different
MET mutation (N1118Y) was found in a lung metastasis
of the large intestine [28]. The MET mutations, R970C
and T992I, were detected in 8 out of 239 C-07 colon
cancers. These mutations correspond to MET-R988C
and MET-T1010I, respectively, in the long form of MET
which is the isoform referred to in the COSMIC data-
base [29]. The R970C and T992I mutations are located
in the juxtamembrane segment of the protein and were
detected in lung carcinoma [30]. These mutations, when
introduced into a lung cell line, increased focus forma-
tion, formation of colonies in soft agar, cell motility, and
migration. These mutations also resulted in constitutive
tyrosine phosphorylation on several cellular proteins
including paxillin at key tyrosine residues and may
account for the increased motility of cells with this
mutation. Another critical amino acid in this location is
a Ser 985, which, when phosphorylated, has been found
to diminish MET signaling [31]. If phosphorylation at
Thr residue 992 (1010) reduces signaling, then the
R992I mutation would inhibit this negative feedback and
may result in constitutive signaling [30].
If MET mutations confer an alternative activated sig-
naling pathway, then these mutations could also confer
resistance to anti-EGFR-based therapies or provide a
new target for directed therapies. Therapeutic drugs
have been developed to specifically target MET,i n c l u d -
ing small molecule kinase inhibitors, anti-MET mono-
clonal antibodies, and inhibitors of HGF, the MET
ligand. Invitro assays have demonstrated that a number
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signaling, decrease cell viability, and limit cell motility
a n dm i g r a t i o ni nv i t r o[ 3 2 ] .T h es m a l lm o l e c u l eA R Q
197, a kinase inhibitor, has entered phase II clinical
trials so may represent a possible therapeutic strategy
for some colon tumors.
To our knowledge, this is also one of the most
exhaustive analyses of mutation profiling of metastatic
lymph nodes and their corresponding primary colon
tumors. Our analysis showed that a majority of samples
were concordant (89.7%) but in a few samples mutations
were detected only in the primary tumor and not in the
metastatic lymph node. Also in samples with 2 co-
occurring mutations, the ratio of the double mutations
varied in primary and lymph node tumors. Discordance
in the genetic profile between primary tumors and the
metastatic lymph nodes has been observed [33]. Such
data may indicate that tumor cell migration selects dif-
ferent cell populations from the one in the primary
tumor. However, it is also possible that these mutational
differences between the lymph node and the primary
tumor are a result of tumor heterogeneity.
Another interesting observation in our study was that
BRAF mutations were significantly correlated with
poorly differentiated tumors and the prevalence of
mucin; similar observations have been reported [25,26].
These characteristics are both associated with a worse
prognosis and are consistent with other reports associat-
ing BRAF mutations with a bad prognosis [3]. However,
in our study we found that there were 2 metastatic
lymph nodes that did not maintain the BRAF mutation
present in the corresponding primary tumor, suggesting
that BRAF mutations are not essential for metastatic
spread to the lymph node in all tumors. Clearly, addi-
tional studies would be required to understand these
apparent inconsistencies; additional lymph node samples
are not currently available but could be the subject of
further studies when samples become available [3].
Conclusions
The Sequenom platform provided a superior technology
for the screening of 238 common hot spot cancer muta-
tions in 19 genes. The frequent occurrence of KRAS,
PIK3CA,a n dBRAF was confirmed, and mutations not
detected before in colon cancer were found in MET and
ABL1. Twenty-five assays from the OncoCarta were
replexed to form a new panel, termed ColoCarta, which
will be used to screen an additional 800 tumors from
NSABP clinical trial C0-7 with the purpose of identify-
ing prognostic or predictive markers for stage II and III
colon cancer.
Note Added in Proof: Although MET-R988C and
MET-T1010I mutations were listed in COSMIC as
somatic cancer mutations, these nucleotide changes
correspond to SNPs rs34589476 and rs56391007 in the
NCBI SNP data base, respectively. The frequency for
these SNPs is unknown so whether these nucleotide
changes are associated with cancer is unknown.
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